Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Daunorubicin and platelet function

E M Pogliani, R Fantasia, G Lambertenghi-Deliliers

    Thrombosis and Haemostasis
    |February 23, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Unusual presentation of recurrent subtrochanteric non-union in a patient with hip arthrodesis: A case report.

    Injury·2018
    Same author

    Periprosthetic acetabular fractures: A New classification proposal.

    Injury·2018
    Same author

    Why a surgically treated humeral shaft fracture became a nonunion: review of 11 years in two trauma centers.

    Musculoskeletal surgery·2017
    Same author

    Distal-third diaphyseal fractures of the humerus: choice of approach and surgical treatment.

    Musculoskeletal surgery·2016
    Same author

    Cost-Effectiveness Analysis of Induction Regimens Containing Anthracyclines in Adult Acute Myelogenous Leukemia.

    Leukemia & lymphoma·2016
    Same author

    P-Glycoprotein Expression in Acute Myeloid Leukaemia Cells at Diagnosis: Its relationship to Daunorubicin or Idarubicin Induction Therapy and Survival.

    Hematology (Amsterdam, Netherlands)·2016

    Daunorubicin inhibits key platelet functions like aggregation and release reactions in vitro. This drug-induced thrombocytopathy may contribute to bleeding complications during chemotherapy.

    Area of Science:

    • Hematology
    • Pharmacology
    • Oncology

    Background:

    • Daunorubicin is an anthracycline chemotherapy agent.
    • Platelet dysfunction can lead to bleeding complications in cancer patients.

    Purpose of the Study:

    • To investigate the in vitro effects of Daunorubicin on various platelet functions.
    • To determine if Daunorubicin damages platelet membranes at clinical concentrations.

    Main Methods:

    • Platelet aggregation assays (collagen and thrombin-induced).
    • Measurement of platelet release reaction, prostaglandin synthesis, and platelet factor 3 availability.
    • Platelet uptake of 14C-serotonin and electron microscopy.
    • Reptilase clot-retraction assay.

    Related Experiment Videos

    Main Results:

    • Daunorubicin inhibited platelet aggregation, release reactions, prostaglandin synthesis, and platelet factor 3 availability in a dose- and time-dependent manner.
    • Clinical concentrations of Daunorubicin did not damage platelet membranes.
    • High doses induced platelet lysis, confirmed by electron microscopy.
    • Daunorubicin caused irreversible inhibition of clot retraction.

    Conclusions:

    • Daunorubicin induces in vitro thrombocytopathy by impairing platelet functions without damaging the cellular membrane at clinical doses.
    • This platelet dysfunction may contribute to the hemorrhagic diathesis observed during Daunorubicin therapy.